OBJECTIVE: We describe longitudinal clinical and electrophysiologic evaluation of Charcot-Marie-Tooth disease type 1A (CMT-1A) in infancy and early childhood. BACKGROUND: The clinical picture and electrophysiologic evaluation of CMT-1A during the age of nerve conduction maturation have not been documented. DESIGN/ METHODS: Twenty at-risk children from six unrelated CMT-1A families were examined in the first 5 years of life. Initial ages were 1 month to 4 years (mean, 1.5 years) and final ages 4 to 19 years (mean, 9 years). All subjects had two or more motor and sensory conduction velocities (MCV and SCV), corrected distal motor latencies (DML), and F-waves. RESULTS: Twelve children were affected. Initially, two of these (17%) had symptoms, whereas five (42%) were symptomatic at the end. Numbers of abnormal examinations at the beginning was six (50%) and at conclusion was 10 (83%). None of the patients were disabled. From 2 years of age, all affected children had abnormal MCV, SVC, F-waves, and DML. Prolonged DML was already present in the first months of life and preceded slowing of MCV in three cases. CONCLUSION: The electrophysiologic studies were concordant with the presence or absence of the CMT-1A DNA duplication. In most CMT-1A patients, symptoms appear in early childhood, although the florid clinical picture does not occur until the second decade of life. Serial electrophysiologic studies can detect the CMT-1A gene carrier in infancy.
OBJECTIVE: We describe longitudinal clinical and electrophysiologic evaluation of Charcot-Marie-Tooth disease type 1A (CMT-1A) in infancy and early childhood. BACKGROUND: The clinical picture and electrophysiologic evaluation of CMT-1A during the age of nerve conduction maturation have not been documented. DESIGN/ METHODS: Twenty at-risk children from six unrelated CMT-1A families were examined in the first 5 years of life. Initial ages were 1 month to 4 years (mean, 1.5 years) and final ages 4 to 19 years (mean, 9 years). All subjects had two or more motor and sensory conduction velocities (MCV and SCV), corrected distal motor latencies (DML), and F-waves. RESULTS: Twelve children were affected. Initially, two of these (17%) had symptoms, whereas five (42%) were symptomatic at the end. Numbers of abnormal examinations at the beginning was six (50%) and at conclusion was 10 (83%). None of the patients were disabled. From 2 years of age, all affected children had abnormal MCV, SVC, F-waves, and DML. Prolonged DML was already present in the first months of life and preceded slowing of MCV in three cases. CONCLUSION: The electrophysiologic studies were concordant with the presence or absence of the CMT-1A DNA duplication. In most CMT-1A patients, symptoms appear in early childhood, although the florid clinical picture does not occur until the second decade of life. Serial electrophysiologic studies can detect the CMT-1A gene carrier in infancy.
Authors: L Kalaydjieva; D Gresham; R Gooding; L Heather; F Baas; R de Jonge; K Blechschmidt; D Angelicheva; D Chandler; P Worsley; A Rosenthal; R H King; P K Thomas Journal: Am J Hum Genet Date: 2000-05-30 Impact factor: 11.025
Authors: José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2015-04-01 Impact factor: 4.849
Authors: Stephanie A Amici; William A Dunn; Andrew J Murphy; Niels C Adams; Nicholas W Gale; David M Valenzuela; George D Yancopoulos; Lucia Notterpek Journal: J Neurosci Date: 2006-01-25 Impact factor: 6.167
Authors: José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros Journal: J Neurol Date: 2011-05-18 Impact factor: 4.849
Authors: F Manganelli; C Pisciotta; M M Reilly; S Tozza; A Schenone; G M Fabrizi; T Cavallaro; G Vita; L Padua; F Gemignani; M Laurà; R A C Hughes; A Solari; D Pareyson; L Santoro Journal: Eur J Neurol Date: 2016-07-14 Impact factor: 6.089
Authors: Elena Gallardo; Kristl G Claeys; Eva Nelis; Antonio García; Ana Canga; Onofre Combarros; Vincent Timmerman; Peter De Jonghe; José Berciano Journal: J Neurol Date: 2008-06-17 Impact factor: 4.849
Authors: Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik Journal: BMC Med Date: 2009-11-12 Impact factor: 8.775
Authors: Elena Gallardo; Antonio García; César Ramón; Elías Maraví; Jon Infante; Itziar Gastón; Ángel Alonso; Onofre Combarros; Peter De Jonghe; José Berciano Journal: J Neurol Date: 2009-12 Impact factor: 4.849